Skip to main content
Premium Trial:

Request an Annual Quote

Former Gemini CEO Paul Kelly Takes Helm at Orchid

NEW YORK, May 28 - Orchid Biosciences has appointed Paul Kelly as its new CEO, filling a position left vacant when Dale Pfost left in December 2002, the company announced today.


Kelly, 43, is an Australian-born endocrinologist and the former CEO of Gemini Genomics, which he co-founded in 1995. Gemini, a clinical genomics company that collected genetic, clinical, and environmental data from different human populations and analyzed this data to look for drug targets, merged with Sequenom in 2001.


Since leaving Gemini, Kelly founded Nanovis, a materials science company, and AgaMatrix, a medical devices  company. He most recently held the CEO post at data analysis company OmniViz.


"We believe that Paul has the right mix of vision and hands-on expertise in the commercialization of clinical genetics, genoprofiling and research services for the biomedical and biotechnology sectors to take Orchid to its next stage of growth," said George Poste, chairman of Orchid, in a statement.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.